<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118482</url>
  </required_header>
  <id_info>
    <org_study_id>130312</org_study_id>
    <secondary_id>ISRCTN51802652</secondary_id>
    <nct_id>NCT00118482</nct_id>
  </id_info>
  <brief_title>Clinical Trial for the Prevention of Vasovagal Syncope</brief_title>
  <official_title>A Randomized Clinical Trial of Fludrocortisone for Vasovagal Syncope: The Second Prevention of Syncope Trial (POST II)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Canadian Institutes of Health Research (CIHR)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main question in the study is whether people taking fludrocortisone are less likely to
      faint than people taking an inactive pill called a placebo.

      Fludrocortisone is a drug that stimulates the body to retain salt and water. The
      investigators know from some studies that it might prevent people from fainting at home and
      in the community, while they are carrying on with their lives. There is some evidence that
      salt and water retention help prevent fainting, but no one has a clear idea about whether
      this is true. This study will try to determine if that is true.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      About 10% of adults faint recurrently. These patients are often highly symptomatic, have
      problems with employment and driving, and have well-documented reduced quality of life. There
      are no therapies that have withstood the test of adequately conducted and credible randomized
      clinical trials.

      There is ample evidence of the importance of blood volume in the pathophysiology of vasovagal
      syncope. Fludrocortisone acetate is a corticosteroid with a mild enhancement of
      glucocorticoid activity and a marked increase in mineralocorticoid activity. It has no
      appreciable glucocorticoid effect at doses between 0.05 to 0.2 mg, which are the commonly
      used clinical doses for various disorders requiring mineralocorticoid adrenal replacement.
      The acute actions of fludrocortisone acetate are sodium and water retention, at the expense
      of urinary potassium excretion. Blood volume expansion with either dietary salt
      supplementation or fludrocortisone is often recommended by clinicians for the treatment of
      vasovagal syncope despite a paucity of good evidence for their efficacy. Four clinical
      studies suggest its utility in the prevention of syncope. Fludrocortisone might decrease the
      incidence of vasovagal syncope, but the quality of the evidence supporting its use is poor.
      There are no randomized, placebo-controlled trials of fludrocortisone for the prevention of
      vasovagal syncope. In this 5-year study the investigators will test the hypothesis that
      fludrocortisone prevents recurrences of vasovagal syncope.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2005</start_date>
  <completion_date type="Actual">July 2011</completion_date>
  <primary_completion_date type="Actual">July 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure Will be the Recurrence of Syncope in Follow up Period.</measure>
    <time_frame>Within 12 months</time_frame>
    <description>This will be measured in terms of number of patients that had at least 1 syncopal spell in the 12 month follow up period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The Frequency of Syncope Will be the First Secondary Outcome Measure.</measure>
    <time_frame>Within 12 months</time_frame>
    <description>Frequency will be reported as 12- month syncope event rates (%)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presyncope Frequency, Duration, and Intensity Will be the Second Secondary Outcome Measures, Both Alone and in a Composite Score.</measure>
    <time_frame>Within 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Will be the Third Secondary Outcome Measure. The Investigators Will Compare the Quality of Life in Treated and Untreated Patients.</measure>
    <time_frame>12 months</time_frame>
    <description>Quality of life will be the third secondary outcome measure. The investigators will compare the quality of life in patients on fludrocortisone vs placebo</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">213</enrollment>
  <condition>Syncope, Vasovagal, Neurally-Mediated</condition>
  <arm_group>
    <arm_group_label>fludrocortisone acetate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludrocortisone acetate</intervention_name>
    <description>Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
    <arm_group_label>fludrocortisone acetate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Syncope as a cause of loss of consciousness according to European Society of
             Cardiology criteria

          -  &gt; 2 lifetime syncopal spells preceding enrollment

          -  &gt; or = to -2 points on the Syncope Symptom Score for Structurally Normal Hearts

          -  Age &gt; 18 years with informed consent, or age &gt; 14 years with consent and informed
             parental consent

        Exclusion Criteria:

          -  Other causes of syncope, such as ventricular tachycardia, complete heart block,
             postural (orthostatic) hypotension or hypersensitive carotid sinus syndrome

          -  An inability to give informed consent

          -  Important valvular, coronary, myocardial or conduction abnormality or significant
             arrhythmia

          -  Hypertrophic cardiomyopathy

          -  A known intolerance to fludrocortisone

          -  Another clinical need for fludrocortisone that cannot be met with other drugs

          -  A permanent pacemaker

          -  A seizure disorder

          -  A major chronic non cardiovascular disease

          -  Hypertension (blood pressure â‰¥ 130/85 on 2 occasions) or heart failure

          -  Renal dysfunction (baseline glomerular filtration rate reduced below 60 ml/min/1.73m2
             according to the Cockroft-Gault formula)

          -  Diabetes mellitus

          -  Hepatic disease

          -  Glaucoma

          -  Any prior use of fludrocortisone acetate

          -  A 5-minute stand test resulting in diagnosis of postural orthostatic tachycardia
             syndrome or orthostatic hypotension
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>14 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert S. Sheldon, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary, Faculty of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-2195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cardiovascular Specialists</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23225-3838</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Calgary, Faculty of Medicine</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alberta Children's Hospital</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T3B 6A8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Boniface General Hospital</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2H 2A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Elizabeth II, Halifax Infirmary</name>
      <address>
        <city>Halifax</city>
        <state>Nova Scotia</state>
        <zip>B3H 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McMaster University, Hamilton Health Sciences</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen's University</name>
      <address>
        <city>Kingston</city>
        <state>Ontario</state>
        <zip>K7V 2V7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario, London Health Sciences</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa, Ottawa Heart Institute</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1Y 4W7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Michael's Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5B 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut de Cardiologie de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1T 1C8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hopital Sacre Coeur de Montreal</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H4J 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 30, 2005</study_first_submitted>
  <study_first_submitted_qc>June 30, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <results_first_submitted>October 26, 2016</results_first_submitted>
  <results_first_submitted_qc>May 25, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">June 28, 2017</results_first_posted>
  <last_update_submitted>May 25, 2017</last_update_submitted>
  <last_update_submitted_qc>May 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">June 28, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Bob Sheldon</investigator_full_name>
    <investigator_title>Professor of Cardiac Sciences, Medicine and Medical Genetics</investigator_title>
  </responsible_party>
  <keyword>vasovagal syncope</keyword>
  <keyword>randomized clinical trial</keyword>
  <keyword>quality of life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syncope</mesh_term>
    <mesh_term>Syncope, Vasovagal</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludrocortisone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Patients were recruited between October 1998 and April 2003 from university hospitals in Canada, Columbia, the United States and Poland.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Fludrocortisone Acetate</title>
          <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="105">3 patients signed the consent but did not take the study medication.</participants>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="75">210 in the Intention To Treat analysis</participants>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="30"/>
                <participants group_id="P2" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Median age was 30.5 years and 146 were women.</population>
      <group_list>
        <group group_id="B1">
          <title>Fludrocortisone Acetate</title>
          <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="105"/>
            <count group_id="B2" value="105"/>
            <count group_id="B3" value="210"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="28" spread="11.5"/>
                    <measurement group_id="B2" value="31" spread="12"/>
                    <measurement group_id="B3" value="30.5" spread="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="146"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="85"/>
                    <measurement group_id="B2" value="85"/>
                    <measurement group_id="B3" value="170"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure Will be the Recurrence of Syncope in Follow up Period.</title>
        <description>This will be measured in terms of number of patients that had at least 1 syncopal spell in the 12 month follow up period.</description>
        <time_frame>Within 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludrocortisone Acetate</title>
            <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure Will be the Recurrence of Syncope in Follow up Period.</title>
          <description>This will be measured in terms of number of patients that had at least 1 syncopal spell in the 12 month follow up period.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Frequency of Syncope Will be the First Secondary Outcome Measure.</title>
        <description>Frequency will be reported as 12- month syncope event rates (%)</description>
        <time_frame>Within 12 months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Fludrocortisone Acetate</title>
            <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
          </group>
        </group_list>
        <measure>
          <title>The Frequency of Syncope Will be the First Secondary Outcome Measure.</title>
          <description>Frequency will be reported as 12- month syncope event rates (%)</description>
          <units>rate %</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="105"/>
                <count group_id="O2" value="105"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.0" lower_limit="42" upper_limit="94"/>
                    <measurement group_id="O2" value="60.5" lower_limit="46" upper_limit="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Presyncope Frequency, Duration, and Intensity Will be the Second Secondary Outcome Measures, Both Alone and in a Composite Score.</title>
        <time_frame>Within 12 months</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Will be the Third Secondary Outcome Measure. The Investigators Will Compare the Quality of Life in Treated and Untreated Patients.</title>
        <description>Quality of life will be the third secondary outcome measure. The investigators will compare the quality of life in patients on fludrocortisone vs placebo</description>
        <time_frame>12 months</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data were collected for the length of each participant's time in the trial up to 1 year.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Fludrocortisone Acetate</title>
          <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>fludrocortisone acetate: Fludrocortisone acetate to a maximum of 0.2 mg daily Placebo to a maximum of 0.2 mg daily</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="105"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="105"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Robert S. Sheldon</name_or_title>
      <organization>University of Calgary</organization>
      <phone>403-2208191</phone>
      <email>sheldon@ucalgary.ca</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

